Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Anstey A, Lear JT: Azathioprine: clinical pharmacology and current indications in autoimmune disorders. BioDrugs. 1998 Jan;9(1):33-47.
Marketing Status Prescription; Discontinued
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 72789-129; 51407-182; 46014-1110; 62991-2189; 12780-0300; 51927-2258; 48954-909; 51552-0779; 15308-0732; 42973-143; 68382-120; 38779-0312; 68382-119; 67877-492; 70771-1139; 65649-241; 68382-118; 67877-494; 54766-590; 68462-502; 0378-1005; 71610-124; 60219-2036; 70771-1140; 51927-0071; 65841-602; 68382-003; 71610-306; 42291-071; 60219-2037; 68084-229; 60219-1076; 70771-1141; 49452-0783; 65649-231; 67877-495; 67877-493; 66122-0009
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blindness06.02.02.001; 17.17.01.003--Not Available
Blindness unilateral06.02.02.009; 17.17.01.0160.002154%Not Available
Blister12.01.06.002; 23.03.01.001--Not Available
Blood albumin decreased13.09.01.0010.002154%Not Available
Blood bilirubin increased13.03.01.008--
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood iron decreased13.11.01.0060.002154%Not Available
Blood potassium decreased13.11.01.010--Not Available
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Body temperature increased13.15.01.0010.002872%Not Available
Bone disorder15.02.04.0040.001436%Not Available
Bowen's disease16.03.02.004; 23.08.02.0040.001436%Not Available
Bradycardia02.03.02.002--Not Available
Brain abscess11.01.03.003; 17.06.07.0010.001436%Not Available
Breast cancer16.10.01.001; 21.05.01.003--Not Available
Bronchitis11.01.09.001; 22.07.01.001--
Bronchopulmonary aspergillosis11.03.01.002; 22.07.08.0010.001436%Not Available
Bronchospasm10.01.03.012; 22.03.01.0040.002154%
Burning sensation08.01.09.029; 17.02.06.0010.004308%Not Available
Bursitis15.04.01.0010.001436%Not Available
C-reactive protein increased13.09.01.0070.017232%Not Available
Calculus urinary20.04.02.0010.001436%Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cardiac hypertrophy02.04.02.0170.000375%Not Available
Cardiac tamponade02.06.01.0010.000562%
Cardiogenic shock02.05.01.003; 24.06.02.0060.002872%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene